The Chemotherapy of Human Malignant Melanoma

  • John J. Costanzi
Part of the Cancer Treatment and Research book series (CTAR, volume 9)


In most investigators’ experience over 50% of all malignant melanoma patients present with or subsequently develop surgically incurable metastatic disease. The majority of published experience utilizing anti-cancer drugs in the treatment of malignant melanoma has been with Stage IV or disseminated disease. In general, the response rate of disseminated melanoma to single agent cancer chemotherapy has been discouragingly low. This lack of effective chemotherapeutic agents has led to much frustration in its management. Therefore, it is of increasing importance that these patients be placed on clinical trials that include new agents and combination of new agents with older agents in an attempt to improve response rate and, hopefully, survival.


Single Agent Metastatic Melanoma Advanced Malignant Melanoma Soft Tissue Metastasis True Response Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bellet RE, Mastrangelo MJ, Berd D, Lustbader E: Chemotherapy of metastatic malignant melanoma. In: Human malignant melanoma, Clark WH et al (eds). Grune and Stratton, 1979.Google Scholar
  2. 2.
    Larsen RR, Hill GJ: Improved systemic chemotherapy for malignant melanoma. Am J Surg 122: 36–41, 1971.PubMedCrossRefGoogle Scholar
  3. 3.
    Gumport SL, Wright JC, Golomb FM: The treatment of advanced malignant melanoma with methylene thippohphoramide (Thio-TEPA or TSPA). Ann Surg 147: 232–238, 1958.PubMedCrossRefGoogle Scholar
  4. 4.
    Sykes MP, Karnofsky DA, Philips FS, et al: Clinical studies on triethylene phosphoramide and diethylenephosphoramide, compounds with nitrogen-mustard-like activity. Cancer 6: 142–148, 1953.CrossRefGoogle Scholar
  5. 5.
    Farber S, Appleton R, Downing V, et al: Clinical studies on the carcinolytic action of triethylenephosphoramide. Cancer 6: 135–141, 1953.CrossRefGoogle Scholar
  6. 6.
    Tullis JL: Triethylenephosphoramide in the treatment of disseminated melanoma. JAMA 166: 37–41, 1958.Google Scholar
  7. 7.
    Clifford P, Clift RA, Gillmore JH: Oral melphalan therapy in advanced malignant disease. Br J Cancer 17: 381–390, 1963.PubMedCrossRefGoogle Scholar
  8. 8.
    Holland JF, Regelson W: Studies of phenylalanine nitrogen mustard (CB 3025) in metastatic malignant melanoma of man. Ann NY Acad Sci 68: 1122–1125, 1958.PubMedCrossRefGoogle Scholar
  9. 9.
    Moore GE, Bross IDJ, Ausman R, et al: Effects of chlorambucil (NSC-3088) in 374 patients with advanced cancer. Cancer Chemother Rep 52: 661–666, 1968.PubMedGoogle Scholar
  10. 10.
    Brindley CO, Salvin LG, Potee KG, et al: Further comparative trial of triethylene thio- phosphoramide and mechlorethamine in patients with melanoma and Hodgkin’s disease. J Chron Dis 17: 19–30, 1964.PubMedCrossRefGoogle Scholar
  11. 11.
    Buckner CD, Rudolph RH, Fefer A, et al: High-dose cyclophosphamide therapy for malignant disease: Toxicity, tumor response, and the effects of stored autogolous marrow. Cancer 29: 357–365, 1972.CrossRefGoogle Scholar
  12. 12.
    Bergsagel DE, Levin WC: A prelusive clinical trial of cyclophosphamide Cancer Chemother Rep 8: 120–134, 1960.Google Scholar
  13. 13.
    Haar H, Marshall GJ, Bierman HR, et al: The influence of cyclophosphamide upon neoplastic diseases in man. Cancer Chemother Rep 6: 41–51, 1960.PubMedGoogle Scholar
  14. 14.
    Gottlieb JA, Mendelson D, Serpick AA: An evaluation of large intermittent intravenous doses of cyclophosphamide (NSC-26271) in the treatment of metastatic malignant melanoma. Cancer Chemother Rep 54: 365–367, 1970.PubMedGoogle Scholar
  15. 15.
    Korst DR, Johnson FD, Frenkel EP, et al: Preliminary evaluation of the effect of cyclophosphamide on the course of human neoplasms. Cancer Chemother Rep 7: 1–12, 1960.Google Scholar
  16. 16.
    Schnider BI, Gold GL, Hall T, et al: Preliminary studies with cyclophosphamide. Cancer Chemother Rep 8: 106–111, 1960.Google Scholar
  17. 17.
    Rundles RW, Laszlo J, Garrison FE, et al: The antitumor spectrum of cyclophosphamide. Cancer Chemother Rep 16: 407–411, 1962.PubMedGoogle Scholar
  18. 18.
    Mullins GM, Colvin M: Intensive cyclophosphamide (NSC–26271) therapy for solid tumors. Cancer Chemother Rep 59: 411–419, 1975.PubMedGoogle Scholar
  19. 19.
    Sullivan RD, Miller E, Zurek WZ, et al: Re-evaluation of methotrexate as an anticancer drug. Surg Gynecol Obstet 125: 819–824, 1967.PubMedGoogle Scholar
  20. 20.
    Vogler WR, Huguley CM, Kerr W: Toxicity and antitumor effect of divided doses of methotrexate. Arch Intern Med 115: 285–293, 1965.PubMedGoogle Scholar
  21. 21.
    Burke PJ, Owens AH, Colsky J, et al: A clinical evaluation of prolonged schedule of cytosine arabinoside (NSC-63878). Cancer Res 30: 1512–1515, 1970.PubMedGoogle Scholar
  22. 22.
    Frei E, Bickers JN, Hewlett JS, et al: Dose schedule and antitumor studies of arabinosyl cutosine (NSC-63878). Cancer Res 29: 1325–1332, 1969.PubMedGoogle Scholar
  23. 23.
    Hart JS, Ho DH, George SL, et al: Cytokinetic and molecular pharmacology studies of arabinosylcytosine in metastatic melanoma. Cancer Res 32: 2711–2716, 1972.PubMedGoogle Scholar
  24. 24.
    Moore GE, Bross IDJ, Ausman R, et al: Effects of 5-flourouracil (NSC-19893) in 389 patients with cancer. Cancer Chemother Rep 52: 641–653, 1968.PubMedGoogle Scholar
  25. 25.
    Regelson W, Holland JF, Gold GL, et al: 6-Mercaptopurine (NSC-755) given intravenously at weekly intervals to patients with advanced cancer. Cancer Chemother Rep 51: 277–282, 1967.PubMedGoogle Scholar
  26. 26.
    Fink DJ, Foye LV: 6-Mercaptopurine (NSC-755) given intermittently in high doses: Phase II study. Cancer Chemother Rep 54: 31–34, 1970.PubMedGoogle Scholar
  27. 27.
    Moore GE, Bross IDJ, Ausman R, et al: Effects of 6-mercaptopurine (NSC-755) in 290 patients with advanced cancer. Cancer Chemother Rep 52: 655–660, 1968.PubMedGoogle Scholar
  28. 28.
    Golomb FM, Solowey AC, Postel A, et al: Induced remission of malignant melanoma with actinomycin-D: Immunologic implications. Cancer 20: 656–662, 1967.PubMedCrossRefGoogle Scholar
  29. 29.
    Moore GE, DePaolo JA, Kondo T: The chemotherapeutic effects and complications of actinomycin-D in patients with advanced cancer. Cancer 11: 1204–1214, 1958.PubMedCrossRefGoogle Scholar
  30. 30.
    Costa G, Hreschyshyn MM, Holland JJ: Initial clinical studies with vincristine. Cancer Chemother Rep 24: 39–44, 1962.PubMedGoogle Scholar
  31. 31.
    Gubisch NJ, Norena D, Perlia CP, et al: Experience with vincristine in solid tumors. Cancer Chemother Rep 32: 19–22, 1963.PubMedGoogle Scholar
  32. 32.
    Shaw RK, Bruner JA: Clinical evaluation of vincristine (NSC-67574). Cancer Chemother Rep 42: 45–58, 1964.PubMedGoogle Scholar
  33. 33.
    Reitmeyer EJ, Moertel CG, Blackburn CM: Vincristine (NSC-67574) therapy of adult patients with solid tumors. Cancer Chemother Rep 34: 21–23, 1964.Google Scholar
  34. 34.
    Smart CR, Ottoman RE, Rochlin DB, et al: Clinical experience with vincristine (NSC-67574) in tumors of the central nervous system and other malignant diseases. Cancer Chemother Rep 52: 733–741, 1968.PubMedGoogle Scholar
  35. 35.
    Frei E, Franzino A, Schnider BI, et al: Clinical studies of vinblastine. Cancer Chemother Rep 12: 125–129, 1961.PubMedGoogle Scholar
  36. 36.
    Armstrong JG, Dyke RW, Fouts PJ, et al: Hodgkin’s disease, carcinoma of the breast, and other tumors treated with vinblastine sulfate. Cancer Chemother Rep 18: 49–71, 1962.PubMedGoogle Scholar
  37. 37.
    Acute Leukemia Group B, Eastern Cooperative Group: Neoplastic disease: Treatment with vinblastine. Arch Intern Med 116: 846–852, 1965.Google Scholar
  38. 38.
    Bond WH, Rohn RJ, Bates LH, et al: Treatment of neoplastic diseases with an improved oral preparation of vinblastine sulfate. Cancer 19: 213–219, 1966.PubMedCrossRefGoogle Scholar
  39. 39.
    Hodes ME, Rohn RJ, Bond WH, et al: Vinaleukoblastine: A summary of two and one-half years’ experience in the use of vinblastine. Cancer Chemother Rep 16: 401–406, 1962.PubMedGoogle Scholar
  40. 40.
    Hill JM, Loeb E: Treatment of leukemia, lymphoma, and other malignant neoplasms with vinblastine. Cancer Chemother Rep 15: 41–61, 1961.PubMedGoogle Scholar
  41. 41.
    Falkson G, van Dyk JJ: The chemotherapy of malignant melanoma. S Afr Med J 42: 89–90, 1968.PubMedGoogle Scholar
  42. 42.
    Wright TL, Hurley J, Korst DR, et al: Vinblastine in neoplastic disease. Cancer Res 23: 169–179, 1963.Google Scholar
  43. 43.
    Smart CR, Rochlin DB, Nahum AM, et al: Clinical experience with vinblastine sulfate (NSC-49842) in squamous cell carcinoma and other malignancies. Cancer Chemother Rep 34: 31–45, 1964.PubMedGoogle Scholar
  44. 44.
    Slack NH, Jones R: Single reversal trial of hydroxyurea (NSC-32065) in 91 patients with advanced cancer. Cancer Chemother Rep 54: 53–63, 1970.PubMedGoogle Scholar
  45. 45.
    Cole DR, Beckloff GL, Rousselot LM: Clinical results with hydroxyurea in cancer chemotherapy: Preliminary report. NY State J Med 65: 2132–2136, 1965.Google Scholar
  46. 46.
    Creasey WA, Capizzi RL, DeConti RC: Clinical and viochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065). Cancer Chemother Rep 54: 191–194, 1970.PubMedGoogle Scholar
  47. 47.
    Bolton BH, Kaung DT, Lawton RL, et al: Hydroxyurea (NSC-32065): A phase I study. Cancer Chemother Rep 39: 47–51, 1964.PubMedGoogle Scholar
  48. 48.
    Cassileth PA, Hyman GA: Treatment of malignant melanoma with hydroxyurea. Cancer Res 27: 1843–1845, 1967.PubMedGoogle Scholar
  49. 49.
    Gottlieb JA, Frei E, Luce JK: Dose-schedule studies with hydroxyurea (NSC-32065) in malignant melanoma. Cancer Chemother Rep 55: 277–280, 1971.PubMedGoogle Scholar
  50. 50.
    Nathanson L, Hall TC: Phase II study of hydroxyurea (NSC-32065) in malignant melanoma. Cancer Chemother Rep 51: 503–505, 1967.Google Scholar
  51. 51.
    Lerner HJ, Beckloff GL, Godwin MC: Hydroxyurea (NSC-32065) intermittent therapy in malignant diseases. Cancer Chemother Rep 53: 385–395, 1969.PubMedGoogle Scholar
  52. 52.
    DeVita VT, Serpick A, Carbone PP: Preliminary clinical studies with ibenzmethyzin. Clin Pharmacol Therap 7: 542–546, 1966.Google Scholar
  53. 53.
    Brunner KW, Young CW: A methylhydrazine derivative in Hodgkin’s disease and other malignant neoplasms. Ann Intern Med 63: 69–86, 1965.PubMedGoogle Scholar
  54. 54.
    Backhouse TW, Sicher K: Initial experience with methylhydrazine, a new cytotoxic agent. Clin Radiol 17: 132–135, 1966.PubMedCrossRefGoogle Scholar
  55. 55.
    Lessner HE: BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea): Effects on advanced Hodgkin’s disease and other neoplasia. Cancer 22: 451–456, 1968.PubMedCrossRefGoogle Scholar
  56. 56.
    Ramirez G, Wilson W, Grage T, et al: Phase II evaluation of 1,3-bis(2-chlorethyl)-1- nitrosourea (BCNU: NSC-409962) in patients with solid tumors. Cancer Chemother Rep 56: 787–790, 1972.PubMedGoogle Scholar
  57. 57.
    DeVita VT, Carbone PP, Owens AH, et al: Clinical trials with 1,3-bis (2-chlorethyl)-1- nitrosourea, NSC-409962. Cancer Res 25: 1876–1881, 1965.Google Scholar
  58. 58.
    Hill GJ, Ruess R, Berris R, et al: Chemotherapy of malignant melanoma with dimethyl triazeno imidazole carboxamide (DTIC) and nitrosourea derivatives (BCNU, CCNU). Ann Surg 180: 167–174, 1974.PubMedCrossRefGoogle Scholar
  59. 59.
    Firat D, Tekuzman G: Treatment of solid tumors and lymphomas with methyl-CCNU (NSC-95441): A phase II study. Cancer Chemother Rep 59: 1021–1023, 1975.PubMedGoogle Scholar
  60. 60.
    Tranum BL, Haut A, Rivkin S, et al: A phase II study of methyl-CCNU in the treatment of solid tumors and lymphomas: A Southwest Oncology Group study. Cancer 35: 1148–1153, 1975.PubMedCrossRefGoogle Scholar
  61. 61.
    Ahmann DL, Hahn RG, Bisel HF: Evaluation of 1-(2-chlorethyl)-3-(4-methylcyclohexyl)- 1-nitrosourea (methyl-CCNU, NSC-95411) versus combined imidazole carboxamide (NSC-45388) and vincristine (NSC-67574) in palliation of disseminated malignant melanoma. Cancer 33: 615–618, 1974.PubMedCrossRefGoogle Scholar
  62. 62.
    Young RC, Canellos GP, Chabner BA, et al: Treatment of malignant melanoma with methyl-CCNU. Clin Pharmacol Therap 15: 617–622, 1974.Google Scholar
  63. 63.
    Gottlieb JA, McCredie KB, Hersh EM, et al: Initial clinical studies with 1-(2-chlorethyl)- 3-(4-methylcyclohexyl)-1 -nitrosourea (methyl-CCNU). Proc Am Assoc Cancer Res 13: 79, 1972.Google Scholar
  64. 64.
    Eastern Cooperative Oncology Group Protocol #1672: Personal communication.Google Scholar
  65. 65.
    DeConti RC, Hubbard SP, Pinch P, et al: Treatment of advanced neoplastic disease with 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037). Cancer Chemother Rep 57: 201–207, 1973.PubMedGoogle Scholar
  66. 66.
    Hoogstraten B, Gottlieb JA, Caoili E, et al: CCNU (NSC-79037) in the treatment of cancer: Phase II study. Cancer 32: 38–43, 1973.PubMedCrossRefGoogle Scholar
  67. 67.
    Perloff M, Muggia FM, Ackerman C: Role of nitrosourea (CCNU, NSC-79037) in advanced nonhematologic cancer. Cancer Chemother Rep 58: 421–424, 1974.PubMedGoogle Scholar
  68. 68.
    Ahmann DL, Hahn RG, Bisel HF: A comparative study of 1-(1-chlorethyl)-3-cyclohexyl- 1-nitrosourea (NSC-79037) and imidazole carboxamide (NSC-45388) with vincristine (NSC-67574) in the palliation of disseminated malignant melanoma. Cancer Res 32: 2431–2434, 1972.Google Scholar
  69. 69.
    Broder LE, Hansen HH: 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU, NSC-79037): A comparison of drug administration at four-week and six-week intervals. Eur J Cancer 9: 147–152, 1973.PubMedCrossRefGoogle Scholar
  70. 70.
    Pugh RP, Jacobs EM, Bareman JR, et al: CCNU vs. CCNU -1-vincristine in disseminated melanoma. Proc Am Soc clin Oncol 16: 246, 1975.Google Scholar
  71. 71.
    Andrews NC, Weiss AJ, Ansfield FJ, et al: Phase I study of dibromodulcitol (NSC- 104800). Cancer Chemother Rep 55: 61–65, 1971.PubMedGoogle Scholar
  72. 72.
    Phillips RW, Brook J: Clinical experience with dibromodulcitol (NSC-104800) in solid tumors. Cancer Chemother Rep 55: 567–573, 1971.PubMedGoogle Scholar
  73. 73.
    Whittington RM, Close HP: Clinical experience with mitomycin-C (NSC-26980). Cancer Chemother Rep 54: 195–198, 1970.PubMedGoogle Scholar
  74. 74.
    Godfrey TE, Wilbur DW: Clinical experience with mitomycin-C in large infrequent doses. Cancer 29: 1647–1652, 1972.PubMedCrossRefGoogle Scholar
  75. 75.
    Moore GE, Bross IDJ, Ausman R, et al: Effects of mitomycin-C (NSC-26980) in 346 patients with advanced cancer. Cancer Chemother Rep 52: 657–684, 1968.Google Scholar
  76. 76.
    Rosenbert B: Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften 60: 399–406, 1973.CrossRefGoogle Scholar
  77. 77.
    Chary KK, et al: A phase II study with high dose CisDDP. Wadley Med Bull 6: 37, 1976.Google Scholar
  78. 78.
    Song SY, et al: Cis ciammino dichloroplatinum in the treatment of metastatic melanoma. Clin Res 25:411 A, 1977.Google Scholar
  79. 79.
    Al-Sarraf MA: Clinical trial of cis-platinum plus hydration with and without mannitol in patients with previously treated advanced malignant melanoma. Proc AACR 20: 185, 1979.Google Scholar
  80. 80.
    Luce JK, Thurman WG, Isaacs BL, Talley RW: Clinical trials with the antitumor agent (5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide. Cancer Chemother Rep 54: 119–124, 1970.PubMedGoogle Scholar
  81. 81.
    Johnson RO, Metter G, Wilson W, Hill G, Kremetz E: Phase I evaluation of DTIC and other studies in malignant melanoma in Central Oncology group. Cancer Treat Rep 60: 183–187, 1976.PubMedGoogle Scholar
  82. 82.
    Nathanson L, Wolter, J, Horton J, Colsky J, Schnider BI, Schilling A: Characteristics of prognosis and response to imidazole carboxamide in malignant melanoma. Clin Pharmacol Ther 12: 955–962, 1971.PubMedGoogle Scholar
  83. 83.
    Costanza M, Nathanson L, Costello W, Wolter J, Brunk F, Colsky J, Hall T, Oberfield R, Regelson W: Results of a randomized study comparing DTIC with TIC mustard in malignant melanoma. Cancer 37: 1654–1659, 1976.PubMedCrossRefGoogle Scholar
  84. 84.
    Thigpen T, Morrison F, Baker L: Phase II evaluation of dianhydrogalactitol in treatment of advanced malignant melanoma. AACR 18: 240, 1977.Google Scholar
  85. 85.
    McKelvey EM, Hewlett JS, Thigpen T, Whitecar J: Cyclocytidine chemotherapy for malignant melanoma. Cancer Treat Rep 62: 469–471, 1978.PubMedGoogle Scholar
  86. 86.
    Cecil JW, Quagliana JM, Coltman CA, Al-Sarraf M, Thigpen T, Groppe CW: Evaluation of VP-16-213 in malignant melanoma. Cancer Treat Rep 62: 801–803, 1978.PubMedGoogle Scholar
  87. 87.
    Al-Saraf M, Thigpen T, Groppe CW, Haut A, Padilla F: Piperazinedione in patients with metastatic malignant melanoma. Cancer Treat Rep 62: 1101–1103, 1978.Google Scholar
  88. 88.
    Presant C, Bartolucci A, Ungara P, Oldham R: A phase II trial of piperazinedione in malignant melanoma. Cancer Treat Rep 63: 1367–1369, 1979.PubMedGoogle Scholar
  89. 89.
    Bellet RE, Catalano Rm, Masterangelo MJ, Berd D, Koons LS: Phase II trial of VM26 in patients with metastatic malignant melanoma. Cancer Treat Rep 62: 445–447, 1978.PubMedGoogle Scholar
  90. 90.
    Bodey GP, Gottlieb JA, Burgess MA, Alexanian R: Clinical evaluation of asaley. Med Pediat Oncol 3: 365–371, 1977.CrossRefGoogle Scholar
  91. 91.
    Bellet RE, Catalano RB, Masterangelo MJ, Berd D: Phase II study of 5-azactydine in patients with metastatic melanoma. Med Pediatr Oncol 4: 11–15, 1978.PubMedCrossRefGoogle Scholar
  92. 92.
    Gottlieb J A, Luce JK: Treatment of malignant melanoma with camptothecin (NSC- 100880) Cancer Chemo Rep 56: 103–105, 1972.Google Scholar
  93. 93.
    Budman D, Currie V, Whittes R: Phase II trial of pyrazofurin in malignant melanoma. Cancer Treat Rep 61: 1733–1734, 1977.PubMedGoogle Scholar
  94. 94.
    Eilber FR, Isakoff W: High dose methotrexate therapy for disseminated malignant melanoma. Proc of AACR and ASCO. Page 262, C-104, 1976.Google Scholar
  95. 95.
    Karakousis CP, Carlson M: High dose methotrexate in malignant melanoma. Cancer Treat Rep 63: 1405–1407, 1979.PubMedGoogle Scholar
  96. 96.
    Bellet RE, Catalano RB, Masterangelo MJ, Berd D: Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and nitrosourea. Cancer Treat Rep 62: 2095–2099, 1978.PubMedGoogle Scholar
  97. 97.
    Carbonne PP, Costello W: Eastern Cooperative Oncology Group studies with DTIC. Cancer Treat Rep 60: 193–198, 1976.Google Scholar
  98. 98.
    McKelvey EM, Luce JK, Talley RW, Hersh EM, Hewlett JS, Moon TE: Combination chemotherapy with BCNU, vincristine and DTIC in disseminated malignant melanoma. Cancer 39: 1–4, 1977.PubMedCrossRefGoogle Scholar
  99. 99.
    McKelvey EM, Luce JK, Vaitkevicius VK, Talley RW, Bodey GP, Lane M, Moon TE: BCNU, vincristine, DTIC and chloropromazine for disseminated malignant melanoma. Cancer 39: 5–10, 1977.PubMedCrossRefGoogle Scholar
  100. 100.
    Costanzi JJ, Vaitkevicius VK, Quagliana JM, Hoogstraten B, Coltman CA, Delaney FC: Combination chemotherapy for disseminated malignant melanoma. Cancer 35: 342–346, 1975.PubMedCrossRefGoogle Scholar
  101. 101.
    Carter RD, Krementz EH, Hill GJ, Metter GE, Fletcher WS, Golomb FM, Grage TB, Minton JP, Sparks FC: DTIC and combination therapy for malignant melanoma: Studies with DTIC, BCNU, CCNU and vincristine and hydroxyurea. Cancer Treat Rep 60: 601–609, 1976.PubMedGoogle Scholar
  102. 102.
    Hill GJ, Metter GE, Krementz ET, Fletcher WS, Golomb EM, Ramirez G, Grage TB, Moss SE: DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU and vincristine. Cancer Treat Rep 63: 11–12, 1979.Google Scholar
  103. 103.
    Presant CA, Bartolucci A: Comparison of cyclophosphamide plus 1-day DTIC or 5-day DTIC in metastatic melanoma. AACR 19: 320, 1978.Google Scholar
  104. 104.
    Costanza ME, Nathanson L, Lenhard R, et al: Therapy of malignant melanoma with an imidazole carboxamide and biscchlorethyl nitrosourea. Cancer 30: 1457–1461, 1972.PubMedCrossRefGoogle Scholar
  105. 105.
    Carter RD, Krementz ET: DTIC in combination therapy for metastatic melanoma: A COG cooperative study. Proc Am Assoc Cancer Res 16: 16, 1975.Google Scholar
  106. 106.
    Byrne MJ: Cyclophosphamide, vincristine and proxarbazine in the treatment of malignant melanoma. Cancer 38: 1922–1924, 1976.PubMedCrossRefGoogle Scholar
  107. 107.
    DeWasch G, Bernheim J, Michel J, Lejune F, Kenis Y: Combination chemotherapy with three marginally effective agents: CCNU, vincristine and bleomycin in the treatment of stage III melanoma. Cancer Treat Rep 60: 1273–1276, 1976.Google Scholar
  108. 108.
    Everall JD, Dowd PM: Use of combination chemotherapy with CCNU, bleomycin and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy. Cancer Treat Rep 63: 151–155, 1979.PubMedGoogle Scholar
  109. 109.
    Costanzi JJ: Chemoimmunotherapy for disseminated melanoma. Proc Amer Soc Clin One 21: 747–C611, 1980.Google Scholar
  110. 110.
    Nathanson L, Wittenberg, et al: Pilot study of vinblastine and bleomycin combination in the treatment of metastatic melanoma. Cancer Treat Rep 64: 133–137, 1980.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, The Hague/Boston/London 1983

Authors and Affiliations

  • John J. Costanzi

There are no affiliations available

Personalised recommendations